The vascular endothelium synthesizes and releases a rangeof vasodilators and vasoconstrictors that have key roles in the local regulation of vascular tone. Among those, endothelin (ET) was identified in 1988 by Yanagisawa et al,1 as one of the most potent vasoconstrictors known, and so far, the landmark discovery of ET has led to 22 000 publica-tions. These have revealed that ET exerts its activity by binding to 2 types of receptors, namely, ETA and ETB, with the ETA mediating the majority of the deleterious effects of ET in the kidney, including vasoconstriction, cell prolifera-tion, and fibrosis. ET is an important physiological regulator of blood pressure through its effects on blood vessels, heart, and kidneys, and the ET system can be ...
Introduction. Endothelin-1(ET-1) is an important regulator of kidney function in health and disease...
Proteinuria is a hallmark of chronic kidney disease (CKD) and cardiovascular disease (CVD), and a go...
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the ...
Over 30,000 publications have been published about the vasoconstrictor endothelin-1, which was ident...
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffne...
It is an understatement to say that blood pressure regulationis complex, especially in terms of long...
AbstractDiabetes and arterial hypertension continue to be the main causes of chronic renal failure i...
Endothelin is tightly involved in the regulation of vascular and renal function in health and in dis...
Introduction: Selective antagonists of Endothelin-1 receptors (ERA) have been tested in diabetic and...
The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension account...
Abstract: Endothelin (ET) is an important modulator of renal function through its binding to ETA and...
The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the tr...
Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension...
Endothelin (ET), a potent endothelium-derived vasoconstrictor peptide [1] contributes to the regulat...
The new analyses described in this article were funded by the Medical Research Council (Grant G0801...
Introduction. Endothelin-1(ET-1) is an important regulator of kidney function in health and disease...
Proteinuria is a hallmark of chronic kidney disease (CKD) and cardiovascular disease (CVD), and a go...
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the ...
Over 30,000 publications have been published about the vasoconstrictor endothelin-1, which was ident...
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffne...
It is an understatement to say that blood pressure regulationis complex, especially in terms of long...
AbstractDiabetes and arterial hypertension continue to be the main causes of chronic renal failure i...
Endothelin is tightly involved in the regulation of vascular and renal function in health and in dis...
Introduction: Selective antagonists of Endothelin-1 receptors (ERA) have been tested in diabetic and...
The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension account...
Abstract: Endothelin (ET) is an important modulator of renal function through its binding to ETA and...
The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the tr...
Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension...
Endothelin (ET), a potent endothelium-derived vasoconstrictor peptide [1] contributes to the regulat...
The new analyses described in this article were funded by the Medical Research Council (Grant G0801...
Introduction. Endothelin-1(ET-1) is an important regulator of kidney function in health and disease...
Proteinuria is a hallmark of chronic kidney disease (CKD) and cardiovascular disease (CVD), and a go...
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the ...